Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 12:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 349 matching trials from the live ClinicalTrials.gov search.
Conditions
Brain and Central Nervous System Tumors
Interventions
imatinib mesylate, temozolomide, pharmacological study
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, imatinib mesylate
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
8
States / cities
Chicago, Illinois • Freehold, New Jersey • Hamilton, New Jersey + 3 more
Conditions
Neurofibromatosis, Neurofibromas
Interventions
Gleevec
Drug
Lead sponsor
Kent Robertson
Other
Eligibility
3 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Gastrointestinal Stromal Tumors
Interventions
DS-6157a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Portland, Oregon + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers

NCT00446004
Conditions
Healthy
Interventions
Imatinib Mesylate, Omeprazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Interventions
Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
13
States / cities
Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more
Conditions
Leukemia
Interventions
arsenic trioxide, imatinib mesylate
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Portland, Oregon
Conditions
Gastrointestinal Stromal Tumors
Interventions
Masitinib, Imatinib
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
7
States / cities
Orlando, Florida • Atlanta, Georgia • Detroit, Michigan + 4 more
Conditions
Leukemia, Myeloid, Chronic Phase
Interventions
Imatinib mesylate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
50
States / cities
Mobile, Alabama • Berkeley, California • Campbell, California + 35 more
Conditions
Chronic Myelogenous Leukemia
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
21
States / cities
Birmingham, Alabama • Anaheim, California • Los Angeles, California + 18 more
Conditions
Lymphoblastic Leukemia, Acute
Interventions
Prednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Methotrexate, Cyclophosphamide, Cytarabine, Etoposide, Mercaptopurine, Imatinib, chemotherapy, intrathecal chemotherapy, steroid therapy, hematopoietic stem cell transplantation
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Months to 18 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
2
States / cities
Memphis, Tennessee • Fort Worth, Texas
Conditions
Small Cell Lung Cancer
Interventions
Gleevec
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Gastrointestinal Stromal Tumor
Interventions
regorafenib
Drug
Lead sponsor
Suzanne George, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania
Conditions
Leukemia
Interventions
Imatinib Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia
Interventions
cytarabine, daunorubicin hydrochloride, imatinib mesylate
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Lung Cancer
Interventions
Gleevec and Taxotere
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Conditions
Leukemia
Interventions
filgrastim, cladribine, cytarabine, imatinib mesylate
Biological · Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, New York
Conditions
Chronic Myeloid Leukemia
Interventions
PEG-IFN-a2b
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
3rd Line GIST
Interventions
ST571 + BYL719
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, KIT Positive, PDGFR Positive, Postmenopausal, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Imatinib Mesylate, Letrozole
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
329
States / cities
Burbank, California • Duarte, California • Fremont, California + 223 more
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, imatinib mesylate, methotrexate, methylprednisolone, pegaspargase, vincristine sulfate
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Leukemia
Interventions
CLAG Regimen, Gleevec®
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions
STI571 400 mg, STI571 600 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Portland, Oregon + 1 more